biOasis to Present at The Global Chinese Financial Forum - Shanghai Conference 2017

VANCOUVER, BC--(Marketwired - June 08, 2017) - BIOASIS TECHNOLOGIES INC. (OTCQB: BIOAF) (TSX VENTURE: BTI) announced today that Dr. Mark Day, the chief executive officer of biOasis, will present at the Global Chinese Financial Forum (GCFF) - Shanghai Conference 2017, in Shanghai, China, on June 22, 2017. biOasis Board Chairman, Rob Hutchison, will attend the conference with Dr. Day.

Dr. Day's presentation, "A Ground-Breaking Platform for the Delivery of Therapeutic Compounds Across the Blood-Brain Barrier," will be attended by a wide assortment of private investors, life science companies and investment funds. The GCFF - Shanghai Conference 2017 will be held concurrently with China's largest pharma-focused event, the CPhI China Conference.

"The Chinese pharmaceutical industry is one of the largest in the world with double-digit growth and exceptional opportunities for biOasis," said Dr. Mark Day, CEO, biOasis. "The GCFF - Shanghai Conference 2017 offers biOasis the opportunity to introduce our Transcend Platform to executives and scientists from many of China's largest life science companies and to begin building alliances throughout Asia."

"On a personal note, the conference is my first opportunity to publicly express my excitement about biOasis and to discuss our strategies for the Transcend Platform going forward," said Dr. Day. "I have described Transcend as one of the most unique and promising blood-brain barrier technologies of our time. I look forward to meeting my industry colleagues and establishing new ones, placing biOasis in the mix of growth opportunities the Chinese pharmaceutical industry can offer us."

About Transcend
Transcend is biOasis' proprietary platform for the delivery of therapeutics across the blood-brain barrier to address unmet medical needs in the treatment of metastatic brain cancers as well as neurodegenerative and metabolic diseases. The delivery of therapeutics across the blood-brain barrier represents the single greatest challenge in treating neurological disorders. The ability to effectively and safely transverse the blood-brain barrier with the Transcend peptide carrier, MTfp, offers the opportunity for biOasis to deliver therapeutics into the brain at doses sufficient to have a therapeutic effect.

About biOasis
biOasis Technologies Inc. is a biopharmaceutical company headquartered in the Vancouver, Canada area, focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB). The company is developing and commercializing a proprietary brain delivery technology to address unmet medical needs in the treatment of central nervous system disorders. biOasis trades on the OTCQB under the symbol "BIOAF" and on the TSX Venture Exchange under the symbol "BTI." For more information about the company please visit www.bioasis.ca.

Forward Looking Statements
Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.

On Behalf of the Board of Directors
Rob Hutchison, Chairman of The Board of Directors

"Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release"